Ironwood Pharmaceuticals IRWD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | 33.3%+6.8pp | 26.5%+249pp | -222%-283pp | 61%+4.8pp | |
| Net margin | 8.1%+7.9pp | 0.3%+227pp | -226.4%-269pp | 42.6%-85.1pp | |
| EBITDA margin | 33.9%+7.1pp | 26.8%+249pp | -221.8%-283pp | 61.3%+4.8pp | |
| Returns | |||||
| Return on assets | 6.4%+6.2pp | 0.2%+128pp | -127.5%-143pp | 15.7%-47.0pp | |
| Efficiency | |||||
| Asset turnover | 0.8×-0.1× | 0.9×+0.3× | 0.6×+0.2× | 0.4×-0.1× | |
| Liquidity | |||||
| Current ratio | 1.1×-3.6× | 4.7×+3.8× | 0.8×-29.7× | 30.6×+26.0× | |
| Quick ratio | 1.1×-3.6× | 4.7×+3.8× | 0.8×-29.7× | 30.6×+26.0× | |
| Cash ratio | 0.9×-1.4× | 2.3×+1.9× | 0.3×-25.4× | 25.7×+21.9× | |
| Leverage | |||||
| Debt-to-assets | 0.5×+0.5× | 0×-0.4× | 0.5×+0.4× | 0×-0.1× | |
| Net debt / EBITDA | -0×+0.7× | -0.8×— | —— | -2.5×-0.5× | |
| Interest coverage | 3×+0.2× | 2.8×+48.3× | -45.4×-78.4× | 32.9×+25.5× | |
| Per Share | |||||
| Book value per share | -$1.61+14.7% | -$1.88+15.5% | -$2.23-164% | $3.50-5.0% | |
| Valuation | |||||
| Market capitalization | $632.12M+457% | $708.93M-60.3% | $1.78B-6.1% | $1.9B-11.6% | |
| Enterprise value | $624M+3,024% | $635.86M-66.7% | $1.91B+51.2% | $1.26B-24.2% | |
| Price / earnings | 6.2×— | 805.6×— | —— | 10.9×+6.8× | |
| Price / sales | 1.8×+1.4× | 2×-2.0× | 4×-0.6× | 4.6×-0.6× | |
| EV / EBITDA | 3.1×+2.7× | 6.7×— | —— | 5×-2.1× | |
| EV / sales | 1.7×+1.7× | 1.8×-2.5× | 4.3×+1.2× | 3.1×-1.0× | |
| Earnings yield | 16.2%+44.7pp | 0.1%+56.3pp | -56.2%-65.4pp | 9.2%-15.4pp | |
| PEG ratio | 0×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ironwood Pharmaceuticals's profit margins?
- Ironwood Pharmaceuticals (IRWD) runs a 99.2% gross margin and a 55.4% operating margin, with a 28.3% net margin.
- Where do Ironwood Pharmaceuticals's ratios come from?
- Every ratio is computed from Ironwood Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
